Till­man Gern­gross is bet­ting well over $500M that the pan­dem­ic will nev­er re­al­ly end. Here’s the IPO pitch

4 years ago
Financing
Bioregnum

Bio­gen pressed against the wall as more stake­hold­ers side against Aduhelm; Prime time for CRISPR 3.0?; and more

4 years ago
Weekly

Kad­mon bags a quick win for its graft-ver­sus-host dis­ease drug ahead of Au­gust PDU­FA date

4 years ago
FDA+

FDA sup­ports lim­it­ed dis­tri­b­u­tion of an­ti­smok­ing drug Chan­tix de­spite car­cino­gen risk

4 years ago
FDA+
Manufacturing

JAK in­hibitor PDU­FA dates ex­tend­ed again as safe­ty re­view con­tin­ues; Stem­son se­cures $15M to cure hair loss

4 years ago
News Briefing

Glax­o­SmithK­line trum­pets a PhI­II win in one of Hal Bar­ron's hand­picked drugs, a day af­ter Fi­bro­Gen's face­plant. Will ...

4 years ago
R&D

Polyphor ax­es staff as cash and op­tions dwin­dle

4 years ago
People

Eli Lil­ly part­ner Ab­Cellera finds a CBO in the face of bam­lanivimab strug­gles; Fi­bro­Gen's next CSO walks in­to ...

4 years ago
Peer Review

Re­gen­eron, al­ready an in­sti­tu­tion in NY, earns Cuo­mo's back­ing for a $1.8B ex­pan­sion at Tar­ry­town hive

4 years ago
Financing
Pharma

Short­ly af­ter its lat­est mega-round, Sir­naomics CEO Patrick Lu says it's time to go pub­lic

4 years ago
Financing

Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

4 years ago
R&D
Pharma

Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 ...

4 years ago
Deals
Cell/Gene Tx

Nas­daq rings in Jonathan Lim's next can­cer play, Pfiz­er-backed start­up and Har­vard spin­out with col­lec­tive $534M ...

4 years ago
Financing

A cou­ple weeks af­ter ac­tivist at­tack, Glax­o­SmithK­line un­veils big plans to cre­ate a UK biotech hub

4 years ago
R&D

Alex­ion touts new PhI­II da­ta of Soliris suc­ces­sor as planned As­traZeneca takeover looms

4 years ago
R&D

Pfiz­er set­tles EpiPen price hike law­suits for $345M

4 years ago
Pharma

Ipsen bets up to $363M on an­oth­er shot at a de­bil­i­tat­ing con­di­tion re­lat­ed to Parkin­son's dis­ease

4 years ago
Deals

Safe­ty con­cerns push FDA ad­comm to vote over­whelm­ing­ly against ap­proval for Fi­bro­Gen ane­mia drug

4 years ago
Pharma
FDA+

As in­ves­ti­ga­tions mount and con­tro­ver­sy swirls, Bio­gen fights back against ICER — and then faces an­oth­er unan­i­mous ...

4 years ago
FDA+

'They have shown that this is not some im­pos­si­ble thing': Aca­d­e­m­ic lab copies Google’s big bi­o­log­i­cal break­through

4 years ago
Discovery

CD­MO AM­RI re­brands and snags a pair of small­er com­pa­nies to aid its shift to be­come a glob­al brand name

4 years ago
R&D
Manufacturing

Gen­er­a­tion Bio snaps up Boston area plant as it rolls out a man­u­fac­tur­ing process it thinks will be a game chang­er

4 years ago
R&D
Manufacturing

Catal­ent lands 2 new part­ner­ships, in­clud­ing for glioblas­toma drug; US drops $153M in­to pan­dem­ic pre­pared­ness

4 years ago
Outsourcing
Manufacturing

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

4 years ago
Cell/Gene Tx
Manufacturing
First page Previous page 675676677678679680681 Next page Last page
A service from the Financial Times